Tianyun Liu

PROTINFO: new algorithms for enhanced protein structure predictions

We describe new algorithms and modules for protein structure prediction available as part of the PROTINFO web server. The modules, comparative and de novo modelling, have significantly improved back-end algorithms that were rigorously evaluated at the sixth meeting on the Critical Assessment of Protein Structure Prediction methods. We were one of four server groups invited to make an oral presentation (only the best performing groups are asked to do so). These two modules allow a user to submit a protein sequence and return atomic coordinates representing the tertiary structure of that protein. The PROTINFO server is available at .

Predicting drug side-effects by chemical systems biology

New approaches to predicting ligand similarity and protein interactions can explain unexpected observations of drug inefficacy or side-effects.

Bioinformatics and variability in drug response: a protein structural perspective

Marketed drugs frequently perform worse in clinical practice than in the clinical trials on which their approval is based. Many therapeutic compounds are ineffective for a large subpopulation of patients to whom they are prescribed; worse, a significant fraction of patients experience adverse effects more severe than anticipated. The unacceptable risk–benefit profile for many drugs mandates a paradigm shift towards personalized medicine. However, prior to adoption of patient-specific approaches, it is useful to understand the molecular details underlying variable drug response among diverse patient populations. Over the past decade, progress in structural genomics led to an explosion of available three-dimensional structures of drug target proteins while efforts in pharmacogenetics offered insights into polymorphisms correlated with differential therapeutic outcomes. Together these advances provide the opportunity to examine how altered protein structures arising from genetic differences affect protein–drug interactions and, ultimately, drug response. In this review, we first summarize structural characteristics of protein targets and common mechanisms of drug interactions. Next, we describe the impact of coding mutations on protein structures and drug response. Finally, we highlight tools for analysing protein structures and protein–drug interactions and discuss their application for understanding altered drug responses associated with protein structural variants.

Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding.

The recognition of cryptic small-molecular binding sites in protein structures is important for understanding off-target side effects and for recognizing potential new indications for existing drugs. Current methods focus on the geometry and detailed chemical interactions within putative binding pockets, but may not recognize distant similarities where dynamics or modified interactions allow one ligand to bind apparently divergent binding pockets. In this paper, we introduce an algorithm that seeks similar microenvironments within two binding sites, and assesses overall binding site similarity by the presence of multiple shared microenvironments. The method has relatively weak geometric requirements (to allow for conformational change or dynamics in both the ligand and the pocket) and uses multiple biophysical and biochemical measures to characterize the microenvironments (to allow for diverse modes of ligand binding). We term the algorithm PocketFEATURE, since it focuses on pockets using the FEATURE system for characterizing microenvironments. We validate PocketFEATURE first by showing that it can better discriminate sites that bind similar ligands from those that do not, and by showing that we can recognize FAD-binding sites on a proteome scale with Area Under the Curve (AUC) of 92%. We then apply PocketFEATURE to evolutionarily distant kinases, for which the method recognizes several proven distant relationships, and predicts unexpected shared ligand binding. Using experimental data from ChEMBL and Ambit, we show that at high significance level, 40 kinase pairs are predicted to share ligands. Some of these pairs offer new opportunities for inhibiting two proteins in a single pathway.

Comparative Modeling: The State of the Art and Protein Drug Target Structure Prediction

The goal of computational protein structure prediction is to provide three-dimensional (3D) structures with resolution comparable to experimental results. Comparative modeling, which predicts the 3D structure of a protein based on its sequence similarity to homologous structures, is the most accurate computational method for structure prediction. In the last two decades, significant progress has been made on comparative modeling methods. Using the large number of protein structures deposited in the Protein Data Bank (~65,000), automatic prediction pipelines are generating a tremendous number of models (~1.9 million) for sequences whose structures have not been experimentally determined. Accurate models are suitable for a wide range of applications, such as prediction of protein binding sites, prediction of the effect of protein mutations, and structure-guided virtual screening. In particular, comparative modeling has enabled structure-based drug design against protein targets with unknown structures. In this review, we describe the theoretical basis of comparative modeling, the available automatic methods and databases, and the algorithms to evaluate the accuracy of predicted structures. Finally, we discuss relevant applications in the prediction of important drug target proteins, focusing on the G protein-coupled receptor (GPCR) and protein kinase families.

Prediction of calcium-binding sites by combining loop-modeling with machine learning

BackgroundProtein ligand-binding sites in the apo state exhibit structural flexibility. This flexibility often frustrates methods for structure-based recognition of these sites because it leads to the absence of electron density for these critical regions, particularly when they are in surface loops. Methods for recognizing functional sites in these missing loops would be useful for recovering additional functional information.ResultsWe report a hybrid approach for recognizing calcium-binding sites in disordered regions. Our approach combines loop modeling with a machine learning method (FEATURE) for structure-based site recognition. For validation, we compared the performance of our method on known calcium-binding sites for which there are both holo and apo structures. When loops in the apo structures are rebuilt using modeling methods, FEATURE identifies 14 out of 20 crystallographically proven calcium-binding sites. It only recognizes 7 out of 20 calcium-binding sites in the initial apo crystal structures.We applied our method to unstructured loops in proteins from SCOP families known to bind calcium in order to discover potential cryptic calcium binding sites. We built 2745 missing loops and evaluated them for potential calcium binding. We made 102 predictions of calcium-binding sites. Ten predictions are consistent with independent experimental verifications. We found indirect experimental evidence for 14 other predictions. The remaining 78 predictions are novel predictions, some with intriguing potential biological significance. In particular, we see an enrichment of beta-sheet folds with predicted calcium binding sites in the connecting loops on the surface that may be important for calcium-mediated function switches.ConclusionProtein crystal structures are a potentially rich source of functional information. When loops are missing in these structures, we may be losing important information about binding sites and active sites. We have shown that limited loop modeling (e.g. loops less than 17 residues) combined with pattern matching algorithms can recover functions and propose putative conformations associated with these functions.

Identifying druggable targets by protein microenvironments matching: application to transcription factors.

Druggability of a protein is its potential to be modulated by drug‐like molecules. It is important in the target selection phase. We hypothesize that: (i) known drug‐binding sites contain advantageous physicochemical properties for drug binding, or “druggable microenvironments” and (ii) given a target, the presence of multiple druggable microenvironments similar to those seen previously is associated with a high likelihood of druggability. We developed DrugFEATURE to quantify druggability by assessing the microenvironments in potential small‐molecule binding sites. We benchmarked DrugFEATURE using two data sets. One data set measures druggability using NMR‐based screening. DrugFEATURE correlates well with this metric. The second data set is based on historical drug discovery outcomes. Using the DrugFEATURE cutoffs derived from the first, we accurately discriminated druggable and difficult targets in the second. We further identified novel druggable transcription factors with implications for cancer therapy. DrugFEATURE provides useful insight for drug discovery, by evaluating druggability and suggesting specific regions for interacting with drug‐like molecules.

Relating Essential Proteins to Drug Side-Effects Using Canonical Component Analysis: A Structure-Based Approach.

The molecular mechanism of many drug side-effects is unknown and difficult to predict. Previous methods for explaining side-effects have focused on known drug targets and their pathways. However, low affinity binding to proteins that are not usually considered drug targets may also drive side-effects. In order to assess these alternative targets, we used the 3D structures of 563 essential human proteins systematically to predict binding to 216 drugs. We first benchmarked our affinity predictions with available experimental data. We then combined singular value decomposition and canonical component analysis (SVD-CCA) to predict side-effects based on these novel target profiles. Our method predicts side-effects with good accuracy (average AUC: 0.82 for side effects present in <50% of drug labels). We also noted that side-effect frequency is the most important feature for prediction and can confound efforts at elucidating mechanism; our method allows us to remove the contribution of frequency and isolate novel biological signals. In particular, our analysis produces 2768 triplet associations between 50 essential proteins, 99 drugs, and 77 side-effects. Although experimental validation is difficult because many of our essential proteins do not have validated assays, we nevertheless attempted to validate a subset of these associations using experimental assay data. Our focus on essential proteins allows us to find potential associations that would likely be missed if we used recognized drug targets. Our associations provide novel insights about the molecular mechanisms of drug side-effects and highlight the need for expanded experimental efforts to investigate drug binding to proteins more broadly.

CRALBP ligand and protein interactions

The visual cycle is the complex enzymatic retinoid-processing involved in regenerating bleached rod and cone visual pigments.1 Central to visual cycle physiology is the cellular retinaldehyde-binding protein (CRALBP), a 36kDa cytosolic protein with high affinity for 11-cis-retinal and 11-cis-retinol. CRALBP is expressed in retinal pigment epithelium (RPE) and Muller cells, as well as in ciliary epithelium, iris, cornea, pineal gland and a subset of oligodendrocytes of the optic nerve and brain.2 Its function outside the RPE is not known, although a recent behavioral genetic study suggests that CRALBP may contribute to ethanol preference in mice.3 In the RPE, CRALBP serves as an 11-cis-retinol acceptor in the visual cycle isomerization step and as a substrate carrier for 11-cis-retinol dehydrogenase. 4, 5, 6, 7, 8 These functions require the rapid association and release of retinoid from the CRALBP ligand-binding pocket and involve critical protein interactions. To better understand the visual cycle, we are characterizing CRALBP ligand and protein interactions and retinoid trafficking within the RPE.

Structural insights into the cellular retinaldehyde-binding protein (CRALBP)

Cellular retinaldehyde‐binding protein (CRALBP) is an essential protein in the human visual cycle without a known three‐dimensional structure. Previous studies associate retinal pathologies to specific mutations in the CRALBP protein. Here we use homology modeling and molecular dynamics methods to investigate the structural mechanisms by which CRALBP functions in the visual cycle. We have constructed two conformations of CRALBP representing two states in the process of ligand association and dissociation. Notably, our homology models map the pathology‐associated mutations either directly in or adjacent to the putative ligand‐binding cavity. Furthermore, six novel residues have been identified to be crucial for the hinge movement of the lipid‐exchange loop in CRALBP. We conclude that the binding and release of retinoid involve large conformational changes in the lipid‐exchange loop at the entrance of the ligand‐binding cavity. Proteins 2005.